Ultralife Corporation Reports Second Quarter Results
07-Aug-2025 07:00:20 EDT
Ultralife Corporation Reports Second Quarter Results
GlobeNewswire August 07, 2025
NEWARK, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) — Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2025 with the following results:
Sales of $48.6 million increased 13.0% from $43.0 million for the second quarter of 2024; excluding Electrochem, sales of $39.3 million declined 8.7% due to a 57.2% decrease in Communications Systems sales
Gross profit of $11.6 million, or 23.9% of revenue, compared to $11.6 million, or 26.9% of revenue, for the second quarter of 2024
Operating income of $2.3 million, including one-time non-recurring costs and purchase accounting adjustments of $0.3 million, compared to $3.9 million for the second quarter of 2024
GAAP EPS of $0.05 compared to $0.18 for the second quarter of 2024
Adjusted EBITDA of $4.1 million compared to $5.4 million for the second quarter of 2024
Backlog with high confidence orders of $89 million compared to $95 million exiting the first quarter of 2025
“The second quarter was a challenging period for Ultralife. While the addition of Electrochem lifted revenue, Battery & Energy Products organic sales were essentially flat and Communications Systems sales declined due to delayed purchase orders. We also faced headwinds from tariffs, unfavorable product mix shifts across our business and order timing, which collectively impacted gross profit. Nevertheless, we continued to invest in new product development, with several offerings advancing into validation and production. We also applied the proceeds from our Employee Retention Credit collected during the quarter to prepay some of our acquisition debt, paying down a total of $2.7 million, $2.0 million more than our quarterly debt amortization requirement,” said Mike Manna, President and Chief Executive Officer.
“Notwithstanding the challenges experienced in the second quarter, we expect improved results in the second half of the year and into 2026. We expect our Communications Systems business to rebound from a tough first half, and we are also beginning to see early purchase orders from long-term new product programs for our battery business, a rebound in demand from our medical and oil & gas customers, sustained growth in global defense spending, and an expanding opportunity pipeline across both businesses,” added Manna. “Our priorities remain converting long-term new product development efforts into revenue, advancing vertical integration in the oil & gas segment, and maintaining a strong focus on operational efficiency initiatives to deliver sustainable profitable growth and maximizing the value of our global brand.”
Second Quarter 2025 Financial Results
Revenue was $48.6 million, an increase of $5.6 million, or 13.0%, as compared to revenue of $43.0 million for the second quarter of 2024. Battery & Energy Products sales increased 25.0% to $45.9 million compared to $36.7 million last year reflecting the inclusion of Electrochem Solutions, Inc. (“Electrochem”). Excluding Electrochem, Battery & Energy Products sales were essentially flat year-over-year with government/defense sales increasing 61.1%, reflecting strong demand from a U.S.-based global prime, offset by a 20.4% decrease in commercial sales, primarily reflecting declines in medical and oil & gas sales. Communications Systems sales decreased by 57.2% to $2.7 million compared to $6.3 million for the same period last year, primarily attributable to shipments in the prior year of integrated systems to a major international defense contractor, magnified by delays in the timing of purchase orders during the current period. Our total backlog and high-confidence orders exiting the second quarter was $89 million compared to $95 million reported for the first quarter of 2025, reflecting the timing of order placement.
Gross profit was $11.6 million, or 23.9% of revenue, compared to $11.6 million, or 26.9% of revenue, for the same quarter a year ago. Battery & Energy Products gross margin was 23.6%, compared to 27.1% last year, primarily due to product mix, higher tariff and freight costs and lower factory throughput at some of our locations. Communications Systems gross margin was 28.4% compared to 25.6% last year, primarily due to product mix somewhat muted by lower volume.
Operating expenses were $9.3 million, compared to $7.6 million for the second quarter of 2024, reflecting the inclusion of Electrochem, a 25.3% increase in new product development costs related to continued investment in our product offering, and one-time, non-recurring expenses. Operating expenses were 19.2% of revenue compared to 17.8% of revenue for the year-earlier period.
Operating income was $2.3 million compared to $3.9 million last year. Driven by the 57.2% decline in Communications Systems sales, the decline in Battery & Energy Products gross margin and non-recurring costs, operating margin decreased to 4.6% compared to 9.1% last year.
Other expense, reported below operating income was $1.1 million, comprised of interest expense from the financing of the Electrochem acquisition and foreign currency loss from the weakening of the U.S. dollar, compared to $.1 million for the same period last year. The 2024 amount included a $0.2 million payment from our insurance carrier pertaining to the cyberattack which occurred in the first quarter of 2023.
Net income attributable to Ultralife Corporation was $.9 million or $0.05 per diluted share on a GAAP basis, compared to $3.0 million or $0.18 per diluted share for the second quarter of 2024. Adjusted EPS was $0.07 on a diluted basis for the second quarter of 2025, compared to $0.22 for the 2024 period. Adjusted EPS excludes the provision for deferred taxes which primarily represents non-cash charges for U.S. taxes which we expect will be fully offset by net operating loss carryforwards and other tax credits for the foreseeable future.
Adjusted EBITDA, defined as EBITDA including non-cash, stock-based compensation expense, was $4.1 million for the second quarter of 2025, or 8.5% of sales, compared to $5.4 million, or 12.6% of sales, for the year-earlier period. On a trailing twelve-month basis, adjusted EBITDA was $15.4 million or 8.6% of sales.
See the “Non-GAAP Financial Measures” section of this release for a reconciliation of adjusted EPS to EPS and adjusted EBITDA to net income attributable to Ultralife Corporation.
About Ultralife Corporation
Ultralife Corporation serves its markets with products and services ranging from power solutions to communications and electronics systems. Through its engineering and collaborative approach to problem solving, Ultralife serves government/defense and commercial customers across the globe.
Headquartered in Newark, New York, the Company's business segments include Battery & Energy Products and Communications Systems. Ultralife has operations in North America, Europe and Asia. For more information, visit www.ultralifecorporation.com.
Conference Call Information
Ultralife will hold its second quarter earnings conference call today at Noon ET.
To ensure a fast and reliable connection to our investor conference call, we now require participants dialing in by phone to register using the following link prior to the call: https://register-conf.media-server.com/register/BIbda86e3ea7b342b6944287e49c2d3e9c. This will eliminate the need to speak with an operator. Once registered, dial-in information will be provided along with a personal identification number. Should you register early and misplace your details, you can simply click back on this same link at any time to register and view this information again. A live webcast of the conference call will be available to investors in the Events & Presentations section of the Company's website at http://investor.ultralifecorporation.com. For those who cannot listen to the live broadcast, a replay of the webcast will be available shortly after the call at the same location.
This press release may contain forward-looking statements based on current expectations that involve a number of risks and uncertainties. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions including the impact of tariffs and inflation, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of our new products on a global basis, and disruptions, delays or material price increases in our supply of raw materials and components due to business conditions, new or additional tariffs, global conflicts, weather or other factors not under our control. The Company cautions investors not to place undue reliance on forward-looking statements, which reflect the Company's analysis only as of today's date. The Company undertakes no obligation to publicly update forward-looking statements to reflect subsequent events or circumstances. Further information on these factors and other factors that could affect Ultralife's financial results is included in Ultralife's Securities and Exchange Commission (SEC) filings, including the latest Annual Report on Form 10-K.
ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (Dollars in Thousands)
(Unaudited)
ASSETS
June 30, 2025
December 31, 2024
Current Assets:
Cash
$10,941
$6,854
Trade Accounts Receivable, Net
32,322
29,370
Inventories, Net
50,575
51,363
Prepaid Expenses and Other Current Assets
5,165
9,573
Total Current Assets
99,003
97,160
Property, Plant and Equipment, Net
40,614
40,485
Goodwill
45,406
45,006
Other Intangible Assets, Net
23,839
24,557
Deferred Income Taxes, Net
7,688
8,413
Other Non-Current Assets
4,411
4,830
Total Assets
$220,961
$220,451
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts Payable
$15,029
$14,160
Current Portion of Long-Term Debt
3,438
2,750
Accrued Compensation and Related Benefits
2,674
2,911
Accrued Expenses and Other Current Liabilities
8,757
9,470
Total Current Liabilities
29,898
29,291
Long-Term Debt, Net
47,510
51,502
Deferred Income Taxes
1,400
1,443
Other Non-Current Liabilities
3,508
4,028
Total Liabilities
82,316
86,264
Shareholders' Equity:
Common Stock
2,108
2,107
Capital in Excess of Par Value
192,350
191,828
Accumulated Deficit
(31,698)
(34,442)
Accumulated Other Comprehensive Loss
(2,820)
(4,006)
Treasury Stock
(21,492)
(21,492)
Total Ultralife Equity
138,448
133,995
Non-Controlling Interest
197
192
Total Shareholders' Equity
138,645
134,187
Total Liabilities and Shareholders' Equity
$220,961
$220,451
ULTRALIFE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In Thousands Except Per Share Amounts)
(Unaudited)
Three-Month Period Ended
Six-Month Period Ended
June 30,
June 30,
June 30,
June 30,
2025
2024
2025
2024
Revenues:
Battery & Energy Products
$45,867
$36,683
$92,188
$71,672
Communications Systems
2,694
6,300
7,119
13,238
Total Revenues
48,561
42,983
99,307
84,910
Cost of Products Sold:
Battery & Energy Products
35,032
26,730
69,913
52,733
Communications Systems
1,928
4,690
5,048
9,144
Total Cost of Products Sold
36,960
31,420
74,961
61,877
Gross Profit
11,601
11,563
24,346
23,033
Operating Expenses:
Research and Development
2,318
1,997
4,722
3,753
Selling, General and Administrative
7,027
5,649
13,969
11,300
Total Operating Expenses
9,345
7,646
18,691
15,053
Operating Income
2,256
3,917
5,655
7,980
Other Expense
1,143
71
2,096
527
Income Before Income Taxes
1,113
3,846
3,559
7,453
Income Tax Provision
243
853
810
1,556
Net Income
870
2,993
2,749
5,897
Net Income (Loss) Attributable to Non-Controlling Interest
(9)
24
5
37
Net Income Attributable to Ultralife Corporation
$879
$2,969
$2,744
$5,860
Net Income Per Share Attributable to Ultralife Common Shareholders – Basic
$.05
$.18
$.17
$.36
Net Income Per Share Attributable to Ultralife Common Shareholders – Diluted
$.05
$.18
$.17
$.35
Weighted Average Shares Outstanding – Basic
16,635
16,658
16,634
16,482
Weighted Average Shares Outstanding – Diluted
16,656
16,825
16,671
16,661
Non-GAAP Financial Measures
Adjusted EBITDA
In evaluating our business, we consider and use adjusted EBITDA, a non-GAAP financial measure, as a supplemental measure of our operating performance in addition to GAAP financial measures. We define adjusted EBITDA as net income attributable to Ultralife Corporation before net interest expense, provision for income taxes, depreciation and amortization, and stock-based compensation expense, plus/minus expense/income that we do not consider reflective of our ongoing continuing operations. We reconcile adjusted EBITDA to net income attributable to Ultralife Corporation, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EBITDA as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EBITDA to net income attributable to Ultralife Corporation.
ULTRALIFE CORPORATION AND SUBSIDIARIES CALCULATION OF ADJUSTED EBITDA (Dollars in Thousands) (Unaudited)
Three-Month Period Ended
Six-Month Period Ended
June 30, 2025
June 30, 2024
June 30, 2025
June 30, 2024
Net Income Attributable to Ultralife Corporation
$879
$2,969
$2,744
$5,860
Adjustments:
Interest Expense, Net
992
418
2,024
938
Income Tax Provision
243
853
810
1,556
Depreciation Expense
1,008
789
1,958
1,529
Amortization Expense
410
227
815
455
Stock-Based Compensation Expense
235
159
462
320
Severance Cost for Plant Closure
–
–
150
–
Acquisition and Other Non-Recurring Costs
326
–
518
–
Non-Cash Purchase Accounting Adjustment
20
–
80
–
Adjusted EBITDA
$4,113
$5,415
$9,561
$10,658
Adjusted Earnings Per Share
In evaluating our business, we consider and use adjusted EPS, a non-GAAP financial measure, as a supplemental measure of our business performance. We define adjusted EPS as net income attributable to Ultralife Corporation excluding the provision (benefit) for deferred income taxes divided by our weighted average shares outstanding on both a basic and diluted basis. We believe that this information is useful in providing period-to-period comparisons of our results by reflecting the portion of our tax provision that will be predominantly offset by our U.S. net operating loss carryforwards and other tax credits for the foreseeable future. We reconcile adjusted EPS to EPS, the most comparable financial measure under GAAP. Neither current nor potential investors in our securities should rely on adjusted EPS as a substitute for any GAAP measures and we encourage investors to review the following reconciliation of adjusted EPS to EPS and net income attributable to Ultralife Corporation.
ULTRALIFE CORPORATION AND SUBSIDIARIES CALCULATION OF ADJUSTED EPS (In Thousands Except Per Share Amounts) (Unaudited)
Three-Month Period Ended
June 30, 2025
June 30, 2024
Amount
Per Basic Share
Per Diluted Share
Amount
Per Basic Share
Per Diluted Share
Net Income Attributable to Ultralife Corporation
$879
$.05
$.05
$2,969
$.18
$.18
Deferred Tax Provision
265
.02
.02
744
.04
.04
Adjusted Net Income
$1,144
$.07
$.07
$3,713
$.22
$.22
Weighted Average Shares Outstanding
16,635
16,656
16,568
16,825
Six-Month Period Ended
June 30, 2025
June 30, 2024
Amount
Per Basic Share
Per Diluted Share
Amount
Per Basic Share
Per Diluted Share
Net Income Attributable to Ultralife Corporation
$2,744
$.17
$.16
$5,860
$.36
$.35
Deferred Tax Provision
609
.03
.04
1,394
.08
.09
Adjusted Net Income
$3,353
$.20
$.20
$7,254
$.44
$.44
Weighted Average Shares Outstanding
16,634
16,671
16,482
16,661
Company Contact: Ultralife Corporation Philip A. Fain (315) 210-6110 pfain@ulbi.com
